Manufacturer Payments Tied to Use of More Expensive Medical Devices
By Lori Solomon HealthDay Reporter
TUESDAY, April 23, 2024 -- Intravascular microaxial left ventricular assist device (LVAD) manufacturer payments to cardiologists are associated with increased use of LVADs by cardiologists who perform percutaneous coronary interventions (PCIs), according to a research letter published online April 10 in the Journal of the American Medical Association.
Sanket S. Dhruva, M.D., from the University of California, San Francisco, and colleagues examined whether payments from the LVAD manufacturer to cardiologists performing PCIs were associated with any use of LVADs. The analysis included data from the Open Payments program database linked to Part B claims for a sample of Medicare fee-for-service beneficiaries to identify cardiologists (6,398) performing at least one PCI (2016 to 2018) at hospitals capable of placing both LVADs and intra-aortic balloon pumps.
The researchers found that among the 6,336 cardiologists receiving LVAD payments in individual years, 23.2 percent performed at least one LVAD, while among the 11,222 cardiologists not receiving LVAD payments, 9.5 percent performed at least one LVAD. Receipt of LVAD payments was associated with any LVAD use in the year of payment (adjusted risk ratio, 2.04), as well as in the subsequent year (adjusted risk ratio, 1.90). The highest adjusted risk ratio was seen in the highest tertile of LVAD payment values.
"It is concerning that payments from the manufacturer to cardiologists may be associated with increased use of more expensive medical devices not demonstrated to be more safe or effective," the authors write.
Several authors reported ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023
WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.